Home / Business and Economy / Vertex Pharma: $10B Buy Ignites Future Growth
Vertex Pharma: $10B Buy Ignites Future Growth
9 Sep
Summary
- Vertex Pharmaceuticals' shares trade at $546 with price targets ranging widely.
- The company relies on CF drugs but is diversifying with new acquisitions.
- Analysts remain divided on Vertex's future prospects and stock performance.
Vertex Pharmaceuticals (NASDAQ: VRTX) is currently valued at $546 per share, yet analysts hold differing views, with price targets spanning from $350 to $672. Goldman Sachs, for instance, maintains a "buy" rating and a $653 target, listing Vertex on its highest-conviction list.
The company's established success stems from its innovative medicines for rare diseases, particularly its leading cystic fibrosis (CF) treatments. These therapies provide consistent revenue and earnings, projected to continue until patent exclusivity ends in the late 2030s. Vertex's strategy focuses on less competitive markets for rare conditions.
Vertex is actively seeking to broaden its offerings beyond CF. Recent launches like Casgevy and Journavx have yet to significantly impact revenue. However, a recent $10 billion acquisition of Crinetics Pharmaceuticals bolsters its portfolio with approved medicines like Palsonify for acromegaly and the investigational atumelnant for congenital adrenal hyperplasia, expected to generate over $5 billion in combined peak sales.
The drugmaker also has povetacicept in the pipeline for IgA nephropathy, with regulatory approval sought by year-end. Further pipeline development includes inaxaplin for APOL-1-mediated kidney disease, alongside other assets in mid-to-late-stage clinical trials, complementing its robust CF business.
